U.S. markets closed
  • S&P Futures

    4,407.50
    -14.25 (-0.32%)
     
  • Dow Futures

    34,351.00
    -111.00 (-0.32%)
     
  • Nasdaq Futures

    15,294.50
    -31.50 (-0.21%)
     
  • Russell 2000 Futures

    2,219.90
    -8.40 (-0.38%)
     
  • Crude Oil

    71.78
    -0.19 (-0.26%)
     
  • Gold

    1,754.30
    +2.90 (+0.17%)
     
  • Silver

    22.34
    +0.00 (+0.01%)
     
  • EUR/USD

    1.1727
    -0.0044 (-0.38%)
     
  • 10-Yr Bond

    1.3700
    +0.0390 (+2.93%)
     
  • Vix

    20.81
    +2.12 (+11.34%)
     
  • GBP/USD

    1.3726
    -0.0070 (-0.51%)
     
  • USD/JPY

    109.9880
    +0.2700 (+0.25%)
     
  • BTC-USD

    47,102.59
    -909.33 (-1.89%)
     
  • CMC Crypto 200

    1,193.48
    -32.05 (-2.61%)
     
  • FTSE 100

    6,963.64
    -63.84 (-0.91%)
     
  • Nikkei 225

    30,500.05
    +176.75 (+0.58%)
     

Apellis-Sobi Partnered Pegcetacoplan Shows Clinically Meaningful Improvements in Rare Blood Disorder Study

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Apellis Pharmaceuticals Inc (NASDAQ: APLS) and Swedish Orphan Biovitrum AB (SOBI) have reported positive top-line results from the Phase 3 PRINCE study evaluating Empaveli (pegcetacoplan) in treatment naïve paroxysmal nocturnal hemoglobinuria (PNH) patients.

  • Empaveli demonstrated statistical superiority on the co-primary endpoints of hemoglobin stabilization and reduction in lactate dehydrogenase (LDH) compared to standard of care, which did not include complement inhibitors, at Week 26.

  • 86% of Empaveli-treated patients achieved hemoglobin stabilization compared to 0% of patients on standard of care.

  • Mean LDH in the Empaveli group decreased by 90% from a baseline, compared to 14%.

  • Mean hemoglobin levels in the Empaveli group increased from 9.4 g/dL to 12.1 g/dL compared to an increase from 8.7 g/dL to 9.4 g/dL on the standard of care.

  • 91% of patients on Empaveli were transfusion-free compared to 22% on the standard of care.

  • On the safety front, 9% of patients in the Empaveli group experienced a serious adverse event compared to 17% on the standard of care.

  • One death was reported in each group, and neither was related to treatment.

  • Detailed results from the PRINCE study will be presented at medical congresses.

  • Empaveli is approved in the U.S. for PNH, a rare blood disorder characterized by the destruction of oxygen-carrying red blood cells through extravascular and intravascular hemolysis.

  • Price Action: APLS shares are trading higher by 9.75% at $51.80 in the premarket session on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.